Vedanta Biosciences
Founded Year
2010Stage
Series E | AliveTotal Raised
$339.8MLast Raised
$106.5M | 13 days agoMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
+170 points in the past 30 days
About Vedanta Biosciences
Vedanta Biosciences is a clinical-stage company developing immunotherapies designed to treat immune-mediated and infectious diseases. It offers a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria. The company was founded in 2010 and is based in Cambridge, Massachusetts.
Missing: Vedanta Biosciences's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Vedanta Biosciences's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Vedanta Biosciences
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Vedanta Biosciences is included in 4 Expert Collections, including Synthetic Biology.
Synthetic Biology
238 items
Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.
Cancer
4,784 items
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Omics
275 items
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Vedanta Biosciences Patents
Vedanta Biosciences has filed 20 patents.
The 3 most popular patent topics include:
- Microbiology
- Bacteriology
- Clostridiaceae
Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
10/27/2017 | 9/20/2022 | Clostridiaceae, Disaccharides, Clostridium, Clostridia, Sugar substitutes | Grant |
Application Date | 10/27/2017 |
---|---|
Grant Date | 9/20/2022 |
Title | |
Related Topics | Clostridiaceae, Disaccharides, Clostridium, Clostridia, Sugar substitutes |
Status | Grant |
Latest Vedanta Biosciences News
May 2, 2023
A company developing a potential new category of oral therapies based on defined bacterial consortia has made two big announcements this week (April 25). Vedanta Biosciences, a clinical-stage company, has raised $106.5million to support its lead candidate VE303 that aims to stop recurrent Clostridioides difficile infection (CDI). The company has also announced a phase 2 study of VE202 for ulcerative colitis. It says these are among other development activities. The VE303 study would be the first phase 3 study of a therapeutic candidate based on a defined bacterial consortium, which Vedanta is promoting as a next-generation approach to microbiome therapy. Defined bacterial consortia are products of standardized composition manufactured from cell banks, bypassing the need to rely on donor fecal material of inconsistent composition. The investor syndicate was co-led by new investors AXA IM Alts and The AMR Action Fund, along with existing investors Bill & Melinda Gates Foundation, Skyviews Life Science, Reimagined Ventures, Fiscus Ventures, PEAK6, and Atlantic Neptune. New investors K2 HealthVentures, Korea Investment Partners, Korea Investment & Securities Asia Ltd. and Korea Investment & Securities US, Inc., and existing investors including co-founder PureTech Health, Revelation Partners, QUAD Investment Management, Seventure Partners, Hambro Perks, and Pfizer Inc. also participated. Bernat Olle, co-founder and CEO of Vedanta Biosciences, said: “We are grateful to have the support of our new and existing investors, who share our vision of pioneering microbiome therapeutics based on defined bacterial consortia to transform the lives of patients with serious diseases. “Our Phase 2 clinical data and this new funding enable us to continue advancing the microbiome field beyond products made from fecal donations, and towards pharmaceutical-grade, defined medicines.” The funding will mainly be used to advance the phase 3 study of VE303 and as a proof of concept study of VE202 in ulcerative colitis. The company says that C. difficile causes approximately half a million infections each year in the United States, including up to 165,000 recurring infections and has been associated with up to 45,000 deaths annually. The positive results of the phase 2 study, first reported in October 2021, triggered a $23.8 million contract option from the Biomedical Advanced Research and Development Authority (BARDA) to support a phase 3 clinical study of VE303. This project has been funded in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; BARDA, under contract number 75A5012C00177 for a contract value up to $81.9 million. Copyright - Unless otherwise stated all contents of this web site are © 2023 - William Reed Ltd - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions
Vedanta Biosciences Frequently Asked Questions (FAQ)
When was Vedanta Biosciences founded?
Vedanta Biosciences was founded in 2010.
Where is Vedanta Biosciences's headquarters?
Vedanta Biosciences's headquarters is located at 19 Blackstone Street, Cambridge.
What is Vedanta Biosciences's latest funding round?
Vedanta Biosciences's latest funding round is Series E.
How much did Vedanta Biosciences raise?
Vedanta Biosciences raised a total of $339.8M.
Who are the investors of Vedanta Biosciences?
Investors of Vedanta Biosciences include Seventure Partners, QUAD Investment Management, Bill & Melinda Gates Foundation, Skyviews Life Science, Pfizer and 36 more.
Who are Vedanta Biosciences's competitors?
Competitors of Vedanta Biosciences include Alveolus and 1 more.
Compare Vedanta Biosciences to Competitors
SciBac aims to target Clostridium difficile (C. diff), a potentially fatal and often recurring gastrointestinal infection. Using "Evolutionary" live biotherapeutics, it stops colonization, neutralizes toxins, and directly kills C. diff organisms. The company is also developing a single-strain inhaled biotherapeutic for patients with cystic fibrosis. That therapy aims to break down the problematic mucus in the patient's lungs, while also suppressing dangerous Pseudomonas aeruginosa bacteria.
LISCure Biosciences develops a "bacteria-mediated immunotherapy" that can treat people by itself or be used in combination with other drugs for major indications such as tumors as well as degenerative neurological, autoimmune and metabolic diseases, among others.
Alveolus develops therapeutics for lung diseases such as live biotherapeutics for Bronchopulmonary Dysplasia (BPD), Chronic Obstructive Pulmonary Disease (COPD), Idiopathic Pulmonary Fibrosis (IPF), and Pulmonary Arterial Hypertension (PAH). Alveolus was founded in 2021 and is based in Birmingham, Alabama.
Seres Therapeutics is a clinical-stage therapeutics company developing products to treat a host of disease conditions based on scientific findings related to the human microbiome. The company is developing candidates for the treatment of infectious, metabolic, and inflammatory diseases.
Evelo Biosciences is dedicated to improving the lives of patients globally through the development of a new modality of medicines – monoclonal microbials. Monoclonal microbials are orally delivered medicines that modulate systemic immunology and biology through direct interactions with human cells in the gut. These new medicines are broadly applicable across many diseases – including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory diseases and cancer. Monoclonal microbials have the potential to fundamentally change traditional models of drug discovery and development. By finding and selecting naturally occurring monoclonal microbials with defined therapeutic effects, Evelo can improve the speed, cost and success of drug discovery and development. Evelo's platform enables pharmacological intervention at all stages of disease with naturally occurring, safe and effective monoclonal microbials.
4D Pharma (NASDAQ: LBPS) researches and develops pharmaceutical products in new live biotherapeutic areas in the United Kingdom. The Company's first-generation programs include Blautix, a treatment for irritable bowel syndrome; Thetanix, a treatment for pediatric Crohns; and Rosburix, a treatment for pediatric ulcerative colitis.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.